PeterJacobMohrMD

Cardiology • Sacramento, CA

Adult Congenital Heart Disease, Interventional Cardiology

Physician

Join to view full profile

Dr. Mohr is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Mohr's full profile

Already have an account?

Office
6600 Bruceville Rd
Mob 3; 1st Floor
Sacramento, CA 95823
Phone+1 916-688-2315

Fax+1 314-362-4278
Is this information wrong?

Education & Training

Scripps Clinic/Scripps Green HospitalFellowship, Interventional Cardiology, 2010 - 2011
St Louis University School of MedicineFellowship, Cardiovascular Disease, 2007 - 2010
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2003 - 2006
Tufts University School of MedicineClass of 2003

Certifications & Licensure

CA State Medical License 2010 - 2026
American Board of Internal Medicine Cardiovascular Disease
American Board of Internal Medicine Interventional Cardiology

Clinical Trials

Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Start of enrollment: 2003 Nov 01
Unknown status
Phase 3
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Start of enrollment: 2001 Sep 01
Unknown status
Phase 4
CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy Start of enrollment: 2008 Apr 01
Completed
Phase 2
Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation Start of enrollment: 2014 Jun 01
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

348 citations
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
, , , , , , , , , , , , , , , , , , , , > ;Journal of Clinical Oncology. 2017 Jan 10
19 citations
Clinical outcomes of endovascular treatment of TASC-II C and D femoropopliteal lesions with the Viabahn endoprosthesis ☆
Peter J. Mohr, Jared K. Oyama, Jane T. Luu, Curtiss T. Stinis> ;Cardiovascular Revascularization Medicine. 2015 Dec 1
47 citations
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
Lisa Zimmer, Thomas Eigentler, Felix Kiecker, Jan C. Simon, Jochen Utikal, Peter Mohr, Carola Berking, Eckhart Kämpgen, Edgar Dippel, Rudolf Stadler, Axel Hauschild, M...> ;Journal of Translational Medicine. 2015 Nov 6
947 citations
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean-Jacques Grob, V...> ;Lancet. 2015 Aug 1
37 citations
Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study.
Elisabeth Livingstone, C. Krajewski, Thomas Eigentler, Christine Windemuth-Kieselbach, Sven Benson, Sigrid Elsenbruch, Axel Hauschild, Rainer Rompel, Frank Meiss, A. M...> ;European Journal of Cancer. 2015 Mar 1
8 citations
C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators
Xiaohui Du, Ronald Jay Hinklin, Yumei Xiong, Paul John Dransfield, Jaehyeon Park, Todd J. Kohn, Vatee Pattaropong, Sujen Lai, Zice Fu, Xianyun Jiao, David Chow, Lixia ...> ;ACS Medicinal Chemistry Letters. 2014 Nov 26
1270 citations
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, Evgeny Levchenko, F. de Braud, James Larkin, Claus Garbe, T. Jouary, Axel Hauschild, Jean-Jacques Grob, V. Chiario...> ;The New England Journal of Medicine. 2014 Nov 12
19 citations
Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institu...
Thomas Eigentler, Max Schlaak, Jessica C. Hassel, Carmen Loquai, Ingo Stoffels, Ralf Gutzmer, Sylvie Pätzold, Peter Mohr, Ulrich Keller, Hans Starz, Jens Ulrich, Athan...> ;Journal of Immunotherapy. 2014 Sep 1
17 citations
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Omid Hamid, Robert Ilaria, Claus Garbe, Pascal Wolter, Michele Maio, Thomas E. Hutson, Ana Arance, Paul Lorigan, Jeeyun Lee, Axel Hauschild, Peter Mohr, Marjo Hahka-Ke...> ;Cancer. 2014 Jul 1
24 citations
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.
James F. Blake, John Gaudino, Jason De Meese, Peter Mohr, Mark Joseph Chicarelli, Hongqi Tian, Rustam Ferdinand Garrey, Allen A. Thomas, Christopher S. Siedem, Michael...> ;Bioorganic & Medicinal Chemistry Letters. 2014 Jun 15
30 citations
Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors
Tao Wang, Michelle Lamb, Michael Howard Block, Davies Audrey, Yongxin Han, Ethan Hoffmann, Stephanos Ioannidis, John A. Josey, Zhong-Ying Liu, Paul Lyne, Terry MacInty...> ;ACS Medicinal Chemistry Letters. 2012 Aug 1
1586 citations
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty, Caroline Robert, Peter Hersey, Paul C. Nathan, Claus Garbe, Mohammed M. Milhem, Lev V. Demidov, Jessica C. Hassel, Piotr Rutkowski, Peter Mohr, Rein...> ;The New England Journal of Medicine. 2012 Jul 11
37 citations
Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors
Michel Dietz, Peter Mohr, Bernd Kuhn, Maerki Hans P, Peter Hartman, Armin Ruf, Jörg Benz, Uwe Grether, Matthew Blake Wright> ;Chemmedchem. 2012 Jun 1
3 citations
Adapting the International System of Units to the twenty-first century.
Mills, I. M., Mohr, P. J., Quinn, T. J., Taylor, B. N., Williams, E. R.> ;Philosophical transactions. Series A, Mathematical, physical, and engineering sciences. 2011 Sep 21
23 citations
Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo.
Kurtis D. Davies, Michael J. Humphries, Francis X. Sullivan, Ira von Carlowitz, Yvan Le Huerou, Mohr Peter, Bin Wang, James F. Blake, Lyon Michael, Gunawardana Indrani...> ;Oncology Research. 2011 Jul 1
9 citations
Orally active aminopyridines as inhibitors of tetrameric fructose-1,6-bisphosphatase
Paul Hebeisen, Wolfgang Haap, Bernd Kuhn, Peter Mohr, Hans Peter Wessel, Ulrich Zutter, Stephan Kirchner, Armin Ruf, Jörg Benz, Catherine Joseph, Rubén Alvarez-Sánchez...> ;Bioorganic & Medicinal Chemistry Letters. 2011 Jun 1
104 citations
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.
Thomas Eigentler, Adina Figl, Dietmar Krex, Peter Mohr, Cornelia Mauch, Knut Rass, Azize Bostroem, Oliver Heese, Oliver Koelbl, Claus Garbe, Dirk Schadendorf> ;Cancer. 2011 Apr 15
9 citations
New Insights on the Mechanism of PPAR-targeted Drugs
Uwe Grether, Werner Klaus, Bernd Kuhn, Maerki Hans P, Peter Mohr, Matthew Blake Wright> ;Chemmedchem. 2010 Dec 3
10 citations
Piperidinyl-nicotinamides as potent and selective somatostatin receptor subtype 5 antagonists.
André Alker, Alfred Binggeli, Andreas D. Christ, Luke Green, Maerki Hans P, Rainer E. Martin, Peter Mohr> ;Bioorganic & Medicinal Chemistry Letters. 2010 Aug 1
314 citations
Intramolecular Hydrogen Bonding in Medicinal Chemistry
Bernd Kuhn, Peter Mohr, Martin Stahl> ;Journal of Medicinal Chemistry. 2010 Feb 22
21 citations
Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of Type-2 diabetes
Eric A. Kitas, Peter Mohr, Bernd Kuhn, Paul Hebeisen, Hans Peter Wessel, Wolfgang Haap, Armin Ruf, Jörg Benz, Catherine Joseph, Walter Huber, Ruben Alvarez Sanchez, Ax...> ;Bioorganic & Medicinal Chemistry Letters. 2010 Jan 15
17 citations
Novel, non-peptidic somatostatin receptor subtype 5 antagonists improve glucose tolerance in rodents.
Urs Sprecher, Peter Mohr, Rainer E. Martin, Maerki Hans P, Ruben Alvarez Sanchez, Alfred Binggeli, Basil Künnecke, Andreas D. Christ> ;Regulatory Peptides. 2010 Jan 8
13 citations
Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.
Rainer E. Martin, Peter Mohr, Maerki Hans P, Wolfgang Guba, Christoph Kuratli, Olivier Gavelle, Alfred Binggeli, Stefanie Bendels, Rubén Alvarez-Sánchez, André Alker, ...> ;Bioorganic & Medicinal Chemistry Letters. 2009 Nov 1
24 citations
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: Structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides
Javier de Vicente, Robert Than Hendricks, David Bernard Smith, Fell Jay Bradford, John P. Fischer, Stacey Renee Spencer, Stengel Peter J, Peter Mohr, Robinson John E, ...> ;Bioorganic & Medicinal Chemistry Letters. 2009 Oct 1
15 citations
Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids
Javier de Vicente, Robert Than Hendricks, David Bernard Smith, Fell Jay Bradford, John P. Fischer, Stacey Renee Spencer, Stengel Peter J, Peter Mohr, Robinson John E, ...> ;Bioorganic & Medicinal Chemistry Letters. 2009 Oct 1
Join now to see all

Press Mentions

Bristol Myers Squibb Receives European Commission Approval for Opdivo (Nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC MelanomaAugust 23rd, 2023